AU595221B2 - Fusion proteins, a process for their preparation and their use - Google Patents
Fusion proteins, a process for their preparation and their useInfo
- Publication number
- AU595221B2 AU595221B2 AU60565/86A AU6056586A AU595221B2 AU 595221 B2 AU595221 B2 AU 595221B2 AU 60565/86 A AU60565/86 A AU 60565/86A AU 6056586 A AU6056586 A AU 6056586A AU 595221 B2 AU595221 B2 AU 595221B2
- Authority
- AU
- Australia
- Prior art keywords
- sequence
- amino acids
- genetically codable
- genetically
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 10
- 241000588724 Escherichia coli Species 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
1. Claims for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A fusion protein of the general formula Met - Xn - D' - Y - Z in which n is zero or 1, X is a sequence of 1 to 12 genetically codable amino acids, D' is a sequence of about 70 amino acids in the region of the sequence of amino acids 23 - 93 of the D-peptide in the trp operon of E. coli, Y denotes a sequence of one or more genetically codable amino acids which permits the following amino acid sequence Z to be cleaved off, and Z is a sequence of genetically codable amino acids. 1. Claims for the Contracting State : AT A process for the preparation of a fusion protein of the general formula (1) Met - Xn - D' - Y - Z in which n is zero or 1, X is a sequence of 1 to 12 genetically codable amino acids, D' is a sequence of about 70 amino acids in the region of the sequence of amino acids 23 - 93 of the D-peptide in the trp operon of E. coli, Y denotes a sequence of one or more genetically codable amino acids which permits the following amino acid sequence Z to be cleaved off, and Z is a sequence of genetically codable amino acids, characterized by expressing a gene structure which codes for these fusion proteins in a host cell, and separating the fusion protein.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853526995 DE3526995A1 (en) | 1985-07-27 | 1985-07-27 | FUSION PROTEINS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| DE3526995 | 1985-07-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6056586A AU6056586A (en) | 1987-01-29 |
| AU595221B2 true AU595221B2 (en) | 1990-03-29 |
Family
ID=6276985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU60565/86A Expired AU595221B2 (en) | 1985-07-27 | 1986-07-25 | Fusion proteins, a process for their preparation and their use |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0211299B1 (en) |
| JP (1) | JPH07113040B2 (en) |
| KR (1) | KR950000299B1 (en) |
| AT (1) | ATE50596T1 (en) |
| AU (1) | AU595221B2 (en) |
| CA (1) | CA1336329C (en) |
| DE (2) | DE3526995A1 (en) |
| DK (1) | DK172618B1 (en) |
| ES (1) | ES2000278A6 (en) |
| FI (1) | FI86887C (en) |
| GR (1) | GR861957B (en) |
| HU (1) | HU197356B (en) |
| IE (1) | IE59127B1 (en) |
| IL (1) | IL79522A (en) |
| NO (1) | NO175640C (en) |
| NZ (1) | NZ216967A (en) |
| PT (1) | PT83065B (en) |
| ZA (1) | ZA865556B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3738541A1 (en) * | 1987-11-13 | 1989-05-24 | Hoechst Ag | METHOD FOR INSULATING AND CLEANING HIRUDINE |
| DE3541856A1 (en) * | 1985-11-27 | 1987-06-04 | Hoechst Ag | EUKARYOTIC FUSION PROTEINS, THEIR PRODUCTION AND USE, AND MEANS FOR CARRYING OUT THE PROCESS |
| ATE80913T1 (en) * | 1986-03-12 | 1992-10-15 | Int Minerals & Chem Corp | HYBRID EXPRESSION VECTORS, THEIR PRODUCTION AND USES. |
| EP0371041A1 (en) * | 1987-06-24 | 1990-06-06 | Novo Nordisk A/S | A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation |
| US5179196A (en) * | 1989-05-04 | 1993-01-12 | Sri International | Purification of proteins employing ctap-iii fusions |
| GR1005153B (en) * | 1989-08-29 | 2006-03-13 | The General Hospital Corporation | Fusion proteins their preparation and use |
| US5227293A (en) * | 1989-08-29 | 1993-07-13 | The General Hospital Corporation | Fusion proteins, their preparation and use |
| US5358857A (en) * | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| DE3942580A1 (en) * | 1989-12-22 | 1991-06-27 | Basf Ag | METHOD FOR PRODUCING HIRUDINE |
| PT821006E (en) | 1996-07-26 | 2004-09-30 | Aventis Pharma Gmbh | INSULIN DERIVATIVES WITH ENHANCED ZINC LINK |
| DE19726167B4 (en) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, process for its preparation and pharmaceutical preparation containing it |
| DE19825447A1 (en) | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | New insulin analogues with increased zinc formation |
| DE10114178A1 (en) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinc-free and low-zinc insulin preparations with improved stability |
| DE10227232A1 (en) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Sour insulin preparations with improved stability |
| EP2201120B1 (en) | 2007-09-21 | 2013-12-25 | Cadila Healthcare Limited | Gcsf fusion protein systems suitable for high expression of peptides |
| RS59913B1 (en) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Combination of an insulin and a glp-1 agonist |
| CN102596175A (en) | 2009-07-06 | 2012-07-18 | 赛诺菲-安万特德国有限公司 | Aqueous insulin preparations containing methionine |
| MY180661A (en) | 2009-11-13 | 2020-12-04 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| PT3345593T (en) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine |
| PL2611458T3 (en) | 2010-08-30 | 2017-02-28 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| AR087693A1 (en) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMBINATION FOR USE IN GLUCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| EP3229828B1 (en) | 2014-12-12 | 2023-04-05 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
| TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
| KR20200080747A (en) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same |
| KR20200080748A (en) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | A Method for Purifying Proinsulin Using Anion Exchange Chromatography |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5523686A (en) * | 1985-03-25 | 1986-10-02 | Wellcome Foundation Limited, The | Epidermal growth factor production and method to depilate animals such as sheep |
| AU5668086A (en) * | 1985-03-18 | 1986-10-13 | Genelabs Incorporated | Hybrid genes (eg. IG's & MHC proteins) via lambda library andplasmid casette vector |
| AU5669086A (en) * | 1985-04-08 | 1986-11-05 | Genetic Systems Corporation | Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR68404B (en) * | 1979-06-01 | 1981-12-29 | Univ California | |
| ZA811368B (en) * | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
-
1985
- 1985-07-27 DE DE19853526995 patent/DE3526995A1/en not_active Withdrawn
-
1986
- 1986-07-19 DE DE8686109945T patent/DE3669175D1/en not_active Expired - Lifetime
- 1986-07-19 AT AT86109945T patent/ATE50596T1/en active
- 1986-07-19 EP EP86109945A patent/EP0211299B1/en not_active Expired - Lifetime
- 1986-07-24 ES ES8600544A patent/ES2000278A6/en not_active Expired
- 1986-07-24 FI FI863041A patent/FI86887C/en not_active IP Right Cessation
- 1986-07-25 DK DK198603554A patent/DK172618B1/en not_active IP Right Cessation
- 1986-07-25 IL IL79522A patent/IL79522A/en not_active IP Right Cessation
- 1986-07-25 HU HU863100A patent/HU197356B/en unknown
- 1986-07-25 CA CA000514682A patent/CA1336329C/en not_active Expired - Lifetime
- 1986-07-25 AU AU60565/86A patent/AU595221B2/en not_active Expired
- 1986-07-25 NZ NZ216967A patent/NZ216967A/en unknown
- 1986-07-25 GR GR861957A patent/GR861957B/en unknown
- 1986-07-25 IE IE197786A patent/IE59127B1/en not_active IP Right Cessation
- 1986-07-25 NO NO863000A patent/NO175640C/en unknown
- 1986-07-25 ZA ZA865556A patent/ZA865556B/en unknown
- 1986-07-25 PT PT83065A patent/PT83065B/en unknown
- 1986-07-26 JP JP61176558A patent/JPH07113040B2/en not_active Expired - Lifetime
- 1986-07-26 KR KR1019860006142A patent/KR950000299B1/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5668086A (en) * | 1985-03-18 | 1986-10-13 | Genelabs Incorporated | Hybrid genes (eg. IG's & MHC proteins) via lambda library andplasmid casette vector |
| AU5523686A (en) * | 1985-03-25 | 1986-10-02 | Wellcome Foundation Limited, The | Epidermal growth factor production and method to depilate animals such as sheep |
| AU5669086A (en) * | 1985-04-08 | 1986-11-05 | Genetic Systems Corporation | Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3669175D1 (en) | 1990-04-05 |
| GR861957B (en) | 1986-11-25 |
| IL79522A (en) | 1991-08-16 |
| JPS6229600A (en) | 1987-02-07 |
| FI86887B (en) | 1992-07-15 |
| PT83065A (en) | 1986-08-01 |
| AU6056586A (en) | 1987-01-29 |
| JPH07113040B2 (en) | 1995-12-06 |
| HU197356B (en) | 1989-03-28 |
| DK355486A (en) | 1987-01-28 |
| NO175640C (en) | 1994-11-09 |
| HUT43629A (en) | 1987-11-30 |
| ES2000278A6 (en) | 1988-02-01 |
| IE59127B1 (en) | 1994-01-12 |
| EP0211299A3 (en) | 1988-06-01 |
| EP0211299B1 (en) | 1990-02-28 |
| EP0211299A2 (en) | 1987-02-25 |
| KR950000299B1 (en) | 1995-01-13 |
| PT83065B (en) | 1989-02-28 |
| FI86887C (en) | 1992-10-26 |
| FI863041L (en) | 1987-01-28 |
| ATE50596T1 (en) | 1990-03-15 |
| NO863000D0 (en) | 1986-07-25 |
| NO175640B (en) | 1994-08-01 |
| IL79522A0 (en) | 1986-10-31 |
| DK172618B1 (en) | 1999-03-01 |
| IE861977L (en) | 1987-01-27 |
| DE3526995A1 (en) | 1987-02-05 |
| DK355486D0 (en) | 1986-07-25 |
| CA1336329C (en) | 1995-07-18 |
| NZ216967A (en) | 1988-08-30 |
| ZA865556B (en) | 1987-03-25 |
| FI863041A0 (en) | 1986-07-24 |
| KR870001312A (en) | 1987-03-13 |
| NO863000L (en) | 1987-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU595221B2 (en) | Fusion proteins, a process for their preparation and their use | |
| CA2168429A1 (en) | Expression of fusion polypeptides transported out of cytoplasm without leader sequences | |
| IL81018A (en) | Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process | |
| AU561343B2 (en) | Human immune interferon by recombinant dna | |
| FI853056A0 (en) | Process for the preparation of polypeptide with hirudin activity | |
| DE68922917D1 (en) | KEX2 endoprotease and process for its preparation. | |
| NZ218332A (en) | Il-4(interleukin-4), recombinant production, dna, vectors and pharmaceutical composition | |
| ES8603574A1 (en) | Production of polypeptides with a human gamma-interferon activity. | |
| FI880017A0 (en) | Method for preparing pancreatic trypsin inhibitor variants and DNA, vector and host cell used in the method | |
| PH30889A (en) | Dna encoding equuine-gamma interferon and recombination production of equine ifn-polypeptides. | |
| EP0111814A3 (en) | The cloning and expression of nucleotide sequences encoding bovine growth hormone | |
| AU2795989A (en) | Production of gonorrheal pi proteins and vaccines | |
| AU9026691A (en) | New human recombinant gamma interferon | |
| IE871369L (en) | Recombinant human protein s. | |
| JPS6438099A (en) | Fused protein or dihydrofolate reductase and bradykinin | |
| IE872531L (en) | Preparation of salmon calcitonin by genetic engineering, and¹means for carrying out this process | |
| FI934079L (en) | Method for preparing a fusion protein |